Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs long-term ADT with salvage radiotherapy after prostatectomy
2024-517666-41-00Phase 3Authorised
- Sponsor
- Instituto de Investigación en Oncología Radioterápica
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of goserelin, triptorelin, leuprolide and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by Instituto de Investigación en Oncología Radioterápica. Primary endpoint: 5-year distant metastasis-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
goserelintriptorelinleuprolidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-517666-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517666-41-00.